Cancer Therapy : Preclinical Evidence for Ef fi cacy of New Hsp 90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors


Purpose: Targeting Hsp90 has significant potential as a treatment for prostate cancer, but prototypical agents such as 17-allylamino-17 demethoxygeldanamycin (17-AAG) have been ineffective in clinical trials. Recently, a phase I study aimed at defining a biologically active dose reported the first response to anHsp90 inhibitor in a patient with prostate… (More)

6 Figures and Tables


  • Presentations referencing similar topics